Corindus Vascular Robotics Inc

Corindus Vascular Robotics — Investor Presentation (November 2014)

23 slides from Corindus Vascular Robotics's investor presentation, Nov 19, 2014

  1. Slide 1: Precision Vascular Robotics Corindus Overview November 2014

    Precision Vascular Robotics Corindus Overview November, 2014 1

  2. Slide 2: Forward Looking Statements

    FORWARD LOOKING STATEMENTS THIS PRESENTATION CONTAINS “FORWARD - LOOKING STATEMENTS” (AS SUCH TERM IS DEFINED IN SECTION 27 A OF THE SECURITIES ACT OF 1933 , AS AMENDED, AND SECTION 21 E OF THE SECURITIES EXCHANGE ACT OF 1934 , AS AMENDED, AND INFORMATION RELATING TO THE COMPANY, THAT ARE BASED ON T

  3. Slide 3: Corindus Overview: The leader in precision vascular robotics

    3 Corindus Overview The leader in precision vascular robotics Overview • Only FDA cleared robotic - assisted percutaneous coronary intervention (“PCI”) system • Large US market : 940,000 PCI procedures; 3,250 labs • Provides strong clinical and economic value proposition for patient, hospital and ph

  4. Slide 4: CorPath Robotic PCI: Largest Cath Lab Procedure Innovation

    2014 CorPath Robotic PCI Largest Cath Lab Procedure Innovation CorPath Robotic - assisted PCI 1986 First Stent Procedure 2013 Procedure Unchanged >> 4 PCI procedure remains largely unchanged since introduction • Innovation historically focused on stents and delivery systems • PCI not optimized to re

  5. Slide 5: Vascular Robotics Market

    Vascular Robotics Market CorPath platform potential to expand vascular indications Peripheral (1.5M Procedures) Coronary Peripheral Neuro Structural Corindus IP and Technology 5

  6. Slide 6: Corindus Market Opportunity

    Corindus Market Opportunity FY2018 market estimate 2 6 • New System Sales annual opportunity based on 5 - year replacement cycle in 5,750 US labs and 7,540 OUS labs, at a blended average price per system of $350,000. Prices vary by procedure type and geography. • Non - PCI procedure types are Periph

  7. Slide 7: Product Overview

    Product Overview 7

  8. Slide 8: CorPath Robotic-Assisted PCI System

    CorPath Robotic - Assisted PCI System 8

  9. Slide 9: Today's Cath Lab Challenges

    Today’s Cath Lab Challenges Staff Safety and Health is at Risk • The cath lab is a dangerous environment for workers » Radiation exposure  cancer and cataract risk » Ergonomic Strain  orthopedic injury and pain Procedure Outcomes Not Optimal • Difficulty viewing angiography standing at bedside • I

  10. Slide 10: Safety in a Hazardous Environment

    • Lab ergonomics create awkward working positions • Lead protection exacerbates stress loading – pressures up to 300 psi on discs propagating “interventionalist disc disease” • Radiation exposure – increased risk of brain tumor, leukemia/lymphoma, cataracts Safety in a Hazardous Environment Reduce r

  11. Slide 11: Traditional PCI vs. CorPath Robotic PCI

    Enhanced procedure may i mprove outcomes , economics and safety Traditional PCI vs. CorPath ® Robotic PCI 11 Struggle to see angiography Assess Anatomy Close proximity ergonomic visualization Trial & error, wire spinning Navigate Precise ‘Point & Shoot’ predictability ‘Eyeball’ estimate Measure Anat

  12. Slide 12: Precision Matters in PCI: STLLR Trial

    Stent Deployment Procedural Factors – STLLR Trial • 1,557 patients, 41 US hospitals • Published Journal American College of Cardiology 1 Longitudinal Geographic Miss (LGM) • Independent Core Lab identified LGM • 47.6 % * of patients had LGM stent placements 12 STLLR Trial patients evaluated for LGM

  13. Slide 13: Inaccurate Lesion Assessment

    Inaccurate Lesion Assessment Visual estimation impacts proper stent selection • >65% physicians select stent length based on visual estimation alone 1 – Physician visual estimation is inconsistent 2 • Inaccurate estimates lead to sub - optimal PCI procedure 13 1 65% according to an online survey, Ju

  14. Slide 14: PRECISE vs. Historical Data

    1 Nikolsky E, Pucelikova T, Mehran R, et al. An Evaluation of fluoroscopy time and correlation with outcomes after percutaneous coronary intervention. J Invasive Cardiol, 2007, 19: 208 - 213 2 Weisz G, et al. Safety and Feasibility of Robotic Percutaneous Coronary Intervention. J American College of

  15. Slide 15: Clinical Evidence – Precision Matters

    15 Clinical Evidence – Precision Matters Peer reviewed publication highlights Continued Investment in Clinical Data • Post PRECISE sub - analysis • PRECISION registry post market data collection and analysis vs. manual procedures • Concurrent studies to prove procedure benefits of CorPath robotic pr

  16. Slide 16: Commercial Strategy

    Commercial Strategy 16

  17. Slide 17: Sales Strategy

    Sales Strategy Dedicated system and cassette sales teams 17 System Sales Team • Experienced medical technology sales professionals – System ‘hunters’ • Leveraging both capital and usage models to accelerate sales • Increasing field team • Focused on largest market areas Cassette Sales Team • Experie

  18. Slide 18: Intellectual Property

    Intellectual Property 18

  19. Slide 19: Intellectual Property Overview

    Intellectual Property Overview Expanding on a strong f oundation Continuous “Ring - fencing” all vascular robotics applications: • 30 issued global patents • 54 patents pending: broad application coverage • Continuously building IP portfolio • Pursuing the entire vascular space 19 The only company a

  20. Slide 20: Corindus Vascular Robotics

    Corindus Vascular Robotics

  21. Slide 21: Key Financial Information

    Key Financial Information 21 Key Metrics* Cash, Cash Equivalents and Marketable Securities $6.9 million Private Placements in Q3 2014 $27.5 million Debt** $5.0 million Basic Weighted Average Shares Outstanding 73,360,273 Warrants Outstanding 5,029,865 Stock Options Outstanding 9,046,549 Closing Shar

  22. Slide 22: Corindus Growth Platform

    • PCI is a very large volume medical robotics procedure opportunity; long growth runway • Established initial installed base during 2013 limited launch • PCI commercial foundation and regional show sites in place • Sales team expansion and funnel building across US • Building technology and clinical

  23. Slide 23: About Corindus

    Precision Vascular Robotics The New Standard of Care in Vascular Procedures 23 About Corindus Vascular Robotics Corindus Vascular Robotics is a global technology leader in robotic - assisted percutaneous coronary interventions. The company’s CorPath System is the first medical device that offers int

Corindus Vascular Robotics — Investor Presentation (November 2014) on 6ix